Muscadine Wine Polyphenols for Cognitive Functioning

Overseen By Kylee Mai

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Florida

Must not be taking: Psychostimulants, cannabis products

Disqualifiers: Pregnancy, Diabetes, Mental illnesses, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

25 Participants Needed

Trial Summary

What is the purpose of this trial?

Previous studies have shown that polyphenol-rich foods can positively affect cognitive functions, memory, and mood in humans. We hypothesize that both acute and chronic intake of muscadine wine polyphenols will improve cognitive performance and mood through regulating the HPA axis, alleviating inflammation and oxidative stress, and/or inhibiting monoamine oxidase activities

Will I have to stop taking my current medications?

The trial requires that you stop taking any medication that might influence the study's outcome, such as psychostimulants. If you're on such medications, you may need to stop them to participate.

What evidence supports the effectiveness of Muscadine Wine Polyphenols as a treatment for cognitive functioning?

Research suggests that polyphenols found in muscadine wine may help reduce Alzheimer's disease-related brain issues and memory problems by interfering with harmful protein formations in the brain. Additionally, polyphenols in wine, including those in muscadine, have antioxidant properties that may protect brain cells and improve cognitive health. ^{1 2 3 4 5}

How does the Muscadine Wine Nutraceutical treatment differ from other treatments for cognitive functioning?

Muscadine Wine Nutraceuticals are unique because they use polyphenols from dealcoholized muscadine wine, which may help improve cognitive function by interfering with the formation of harmful protein clusters in the brain, unlike other treatments that might not target these specific mechanisms. ^{1 3 4 6 7}

Research Team

Liwei Gu, PhD

Principal Investigator

University of Florida

Eligibility Criteria

This trial is for healthy adults with a BMI of 18.5-29.9 and body weight over 110 pounds, who drink occasionally to moderately. It's not for smokers, heavy drinkers, pregnant or breastfeeding individuals, those with mental illnesses, cardiovascular or neurological disorders, diabetes, or on certain medications.

Inclusion Criteria

My weight is at least 110 pounds.

Healthy

BMI between 18.5 and 29.9

Exclusion Criteria

I am not taking any medication that could affect the study results.

I have diabetes.

I have a history of heart or brain disorders.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Phase 1

Participants consume either placebo or muscadine wine polyphenol for six weeks

6 weeks

Washout

A 21-day washout period between treatment phases

3 weeks

Treatment Phase 2

Participants switch treatments and consume either muscadine wine polyphenol or placebo for another six weeks

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Muscadine Juice
• Muscadine Wine Nutraceuticals
• Muscadine Wine Polypehnol
• Placebo
• Sprite
• Vodka

Trial Overview The study tests if muscadine wine polyphenols can improve brain health and mood compared to a placebo. Participants will consume these compounds regularly to see if they affect cognitive performance by reducing stress responses and inflammation.

Participant Groups

Group I: Placebo-Intervention Active Control 2 Interventions

Participants in this arm will first consume placebo for six weeks and then muscadine wine polyphenol for another six weeks. The two phases are separated by a 21-day washout period

Group II: Intervention-Placebo Active Control 2 Interventions

Participants in this arm will consume muscadine wine polyphenol for six weeks and then placebo for another six weeks. The two phases are separated by a 21-day washout period

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials

1,428

Recruited

987,000+

Findings from Research

Polyphenols, particularly those found in grapes and berries, have been shown to help delay age-related cognitive decline and neurodegenerative diseases due to their antioxidant and anti-inflammatory properties.

Combining polyphenol consumption with regular physical exercise may enhance cognitive benefits for the aging brain, suggesting a potential for developing neuro-nutraceuticals as functional foods to support brain health.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline During Normal and Pathological Brain Aging. Devi, SA., Chamoli, A.[2020]

Four types of Spanish red wines (Merlot, Tempranillo, Garnacha, and Cabernet-Sauvignon) were studied for their neuroprotective effects, with Merlot showing the highest activity due to its rich polyphenolic content.

The neuroprotection observed in these wines is linked to their ability to scavenge free radicals and protect astrocytes from oxidative stress, suggesting that the polyphenols in red wine contribute to its antioxidant properties.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Study of red wine neuroprotection on astrocytes. Gómez-Serranillos, MP., Martín, S., Ortega, T., et al.[2021]

Moderate consumption of two different red wines, Cabernet Sauvignon and muscadine, showed promise in reducing Alzheimer's disease symptoms in a transgenic mouse model, indicating potential benefits of polyphenolic compounds in these wines.

Cabernet Sauvignon was found to lower the production of amyloid-beta peptides, while muscadine interfered with the harmful aggregation of these peptides, suggesting that different wines may work through unique mechanisms to combat Alzheimer's pathology.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. Ho, L., Chen, LH., Wang, J., et al.[2021]

Regular moderate wine consumption may reduce the risk of chronic diseases linked to inflammation, but the health benefits depend on the type of wine and its polyphenol content.

The review highlights that both alcohol and polyphenols in wine could contribute to health benefits, with the overall effect influenced by individual dietary patterns and the specific mechanisms related to cardiovascular disease development.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Wine and health: state of proofs and research needs. Walzem, RL.[2011]

Moderate wine consumption, particularly red wine, may help prevent chronic diseases due to its high levels of antioxidants like resveratrol, anthocyanins, and catechins.

Resveratrol specifically contributes to cardiovascular health by neutralizing harmful free radicals, protecting brain cells, and reducing blood clot formation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Contribution of Red Wine Consumption to Human Health Protection. Snopek, L., Mlcek, J., Sochorova, L., et al.[2018]

In a study involving rats, specific polyphenolic metabolites from Cabernet Sauvignon red wine were found to accumulate in the brain, with quercetin-3-O-glucuronide significantly reducing the generation of harmful beta-amyloid peptides associated with Alzheimer's disease.

Quercetin-3-O-glucuronide not only interfered with the formation of neurotoxic beta-amyloid aggregates but also improved synaptic transmission and long-term potentiation in the hippocampus, suggesting it may have multiple beneficial effects on Alzheimer's disease mechanisms.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. Ho, L., Ferruzzi, MG., Janle, EM., et al.[2021]

Combining three polyphenolic compounds (grape seed extract, resveratrol, and Concord grape juice extract) showed enhanced protection against cognitive impairments in a mouse model of Alzheimer's disease compared to individual treatments.

The combination treatment significantly reduced total amyloid content in the brain and improved long-term potentiation deficits, suggesting that targeting multiple disease mechanisms with polyphenols may increase therapeutic efficacy for Alzheimer's disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Wang, J., Bi, W., Cheng, A., et al.[2021]

References

1. United States pubmed.ncbi.nlm.nih.gov

Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline During Normal and Pathological Brain Aging. [2020]

2. Netherlands pubmed.ncbi.nlm.nih.gov

Study of red wine neuroprotection on astrocytes. [2021]

3. Netherlands pubmed.ncbi.nlm.nih.gov

Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. [2021]

4. Switzerland pubmed.ncbi.nlm.nih.gov

Wine and health: state of proofs and research needs. [2011]

5. Switzerland pubmed.ncbi.nlm.nih.gov

Contribution of Red Wine Consumption to Human Health Protection. [2018]

6. United States pubmed.ncbi.nlm.nih.gov

Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. [2021]

7. Switzerland pubmed.ncbi.nlm.nih.gov

Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. [2021]